The most important stock-moving data will come from Celldex's lead candidate, glembatumumab vedotin, which is in a phase 2b trial in women with triple negative breast cancer, but data from that trial isn't expected until the second quarter …
NWI1mon
Celldex Therapeutics Inc. (CLDX) agreed to acquire Kolltan Pharmaceuticals Inc., a New Haven, Connecticut-based clinical-stage company that makes cancer drugs, for $62.5 million in stock. Celldex could make additional payments …
At the end of September, CEO Anthony Marucci gave a highly anticipated corporate update at the Cantor Fitzgerald Global Healthcare Conference that caused the company's shares to gain over 22% in just two days leading up to this …
The stock imploded last year after brain cancer patients in the first control group tested against its former lead candidate outperformed historical survival data by a wide margin. When Rintega failed spectacularly, Celldex was lucky enough …
The stock is still showing positive momentum due to strong ... I believe that the positive momentum will continue and that Celldex is still a buy despite recent rallies. Celldex Therapeutics Celldex is a biopharmaceutical involved in the …
A month has gone by since the last earnings report for Celldex Therapeutics, Inc. CLDX. Shares have lost about 4.4% in that time frame, underperforming the market. Will the recent negative trend continue leading up to the stock's next …
Now that we’ve mentioned the most bullish investors, let’s also take a look at some funds that cut their entire stakes in the stock during the third quarter. Interestingly, First Eagle Investment Management cut the biggest position of all the …
This was offset partially by an influx of $11.2 million in cash from a stock offering made under the company's existing agreement with Cantor Fitzgerald. The most significant milestone for Celldex during the third quarter was the …